Corporate Events

Mitsui Fudosan Co., Ltd. provided consolidated earnings forecasts for the year ending March 31, 2026. For the period, the company expects revenue from operations of JPY 2,700,000 million, operating income of JPY 380,000 million, net income attributable to shareholders of the company of JPY 260,000 million, basic earnings per share of JPY 93.78.

From April 1, 2025 to June 30, 2025, the company has repurchased 0 shares, representing 0% for ¥0 million. With this, the company has completed the repurchase of 1,677,700 shares, representing 0.06% for ¥2,088.88 million under the buyback announced on February 7, 2025.

Mitsui Fudosan Co., Ltd. announced that they will report Q1, 2026 results at 3:30 PM, Tokyo Standard Time on Aug 05, 2025

Mitsui Fudosan Co., Ltd. has completed a Fixed-Income Offering in the amount of ¥50 billion. Security Name: 1.382% Unsecured Straight Green Bonds due May 29, 2030 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥50 billion Price\Range: 100% Security Features: Climate Bonds/Green Bonds; Unsecured Coupon Type: Fixed

Mitsui Fudosan Co., Ltd. has completed a Fixed-Income Offering in the amount of ¥50 billion. Security Name: 2.105% Unsecured Straight Green Bonds due May 29, 2035 Security Type: Corporate Bond/Note (Non Convertible) Principal Amount: ¥50 billion Price\Range: 100% Security Features: Climate Bonds/Green Bonds; Unsecured Coupon Type: Fixed

Mitsui Fudosan Co., Ltd., Q4 2025 Earnings Call, May 13, 2025

Mitsui Fudosan Co., Ltd. proposed dividend of JPY 16 per share for the fiscal year ended March 31, 2025. Scheduled date to commence dividend payments is June 30, 2025. Record date is March 31, 2025. Based on the consolidated financial results for the fiscal year ended March 31, 2025 and the Company's shareholder return policy, the Company has decided to increase the fiscal year-end dividend per share to JPY 31.00, JPY 1.00 higher than the latest dividend forecast. The resolution is subject to approval of the Annual Meeting of Shareholders held on June 27, 2025.

Mitsui Fudosan Co., Ltd. expected to report Q1 2026 results on August 8, 2025. This event was calculated by S&P Global (Created on May 10, 2025).

Mitsui Fudosan Co., Ltd., Annual General Meeting, Jun 27, 2025, at 10:00 Tokyo Standard Time. Location: Peacock Room, 2nd Floor, Main Building Imperial Hotel, Tokyo 1-1, Uchisaiwai-cho 1-chome, Chiyoda-ku Tokyo Japan Agenda: To consider the business report and report on the consolidated financial statements for the 113th fiscal year (from April 1, 2024, to March 31, 2025), as well as the results of audits of the consolidated financial statements conducted by the independent auditors and the board of corporate auditors; to consider the report on the non-consolidated financial statements for the 113th fiscal year (from April 1, 2024, to March 31, 2025); to consider the distribution of retained earnings; to consider the election of thirteen directors; to consider the payment of bonuses to directors; to consider the introduction of restricted stock unit system for directors and revision of restricted stock compensation system; and to consider other matters.

Mitsui Fudosan Co., Ltd., Board Meeting, May 09, 2025. Agenda: To pay dividends.

Mitsui Fudosan Co., Ltd., Q4 2025 Earnings Call, May 09, 2025

Mitsui Fudosan Co., Ltd. reported earnings results for the nine months ended December 31, 2024. For the nine months, the company reported sales was JPY 1,676,799 million. Net income was JPY 144,022 million. Basic earnings per share from continuing operations was JPY 51.59. Diluted earnings per share from continuing operations was JPY 51.56.

From February 7, 2025 to March 31, 2025, the company has repurchased 1,677,700 shares, representing 0.06% for ¥2,088.88 million. With this, the company has completed the repurchase of 1,677,700 shares, representing 0.06% for ¥2,088.88 million under the buyback announced on February 7, 2025.

Mitsui Fudosan Co., Ltd., Board Meeting, Mar 27, 2025.

Alpha Corporation, Inc. agreed to acquire YASMO temporary childcare business of Mitsui Fudosan (TSE:8801) and ShareTomorrow on March 25, 2025.

Mitsui Fudosan Co., Ltd. announced that they will report fiscal year 2025 results on May 09, 2025

Frontier Real Estate Investment Corporation (TSE:8964) agreed to acquire 30% stake in Mitsui Shopping Park LaLaport AICHI TOGO from Mitsui Fudosan Co., Ltd. (TSE:8801) for ¥10.9 billion on February 17, 2025. A cash consideration of ¥10.95 billion will be paid by Frontier Real Estate Investment Corporation. As part of consideration, ¥10.95 billion is paid towards assets of Mitsui Shopping Park LaLaport AICHI TOGO. The transaction is subject to approval of offer by acquirer board. The deal has been approved by the board. The expected completion of the transaction is March 26, 2025.

Mitsui Fudosan Co., Ltd., Board Meeting, Feb 07, 2025. Agenda: To repurchase its own shares under Article 156 which is applicable in accordance with Article 165, Paragraph 3 of the Companies Act.

Mitsui Fudosan Co., Ltd. (TSE:8801) announces a share repurchase program. Under the program, the company will repurchase up to 50,000,000 shares, representing 1.8% of its total shares outstanding excluding treasury shares, for a total of ¥45,000 million. The purpose of repurchase program is to enhance returns to shareholders, based on the shareholder return policy, and as part of the company’s flexible capital policy. The repurchase program is valid till January 31, 2026. As of January 31, 2025, the company had 2,773,823,260 shares outstanding excluding treasury shares and had 8,366,451 shares in treasury.

The Board of Directors of Mitsui Fudosan Co., Ltd. has authorized a buyback plan on February 7, 2025.

Mitsui Fudosan Co., Ltd. expected to report Fiscal Year 2025 results on May 9, 2025. This event was calculated by S&P Global (Created on February 7, 2025).

Texas Medical Center (TMC) in partnership with Japan-based organizations Mitsui Fudosan Co. Ltd. and The National Cancer Center announced the launch of the TMC Japan BioBridge and JACT (Japan-Accelerator Cancer Therapeutics and Medical Devices). In 2016, TMC launched the organization's first BioBridge, designed to provide a focused and strategic pathway for international healthcare companies preparing for US market expansion. A delegation from the Texas Medical Center recently visited Tokyo, Japan, for a week of discussions centered on the development of Houston's innovation ecosystem, Japan's bio-industry policies and plans to support life sciences ventures. Participating Japanese institutions included AMED (Japan Agency for Medical Research and Development), NCC (National Cancer Center), MHLW (Ministry of Health, Labour and Welfare), JBA (Japan BioBridge Association), and JETRO (Japan External Trade Organization), among others. The TMC Japan BioBridge Memorandum of Understanding (MoU) was signed on November 5, 2024, in Tokyo, Japan, by William F. McKeon, President and CEO of Texas Medical Center; Takeshi Ozane, General Manager of Mitsui Fudosan Co., Ltd.; and Hitoshi Nakagama, President of the National Cancer Center of Japan. This is the sixth international strategic alliance, including those with the Netherlands, Australia, the United Kingdom, Denmark, and Ireland. Since 2016, TMC's BioBridges have welcomed 88 startup companies specializing in digital health and medical devices across various critical areas such as neurology, oncology, patient engagement, surgery, orthopedics, cardiovascular health, transplantation, intensive care, and ophthalmology. JACT introduces the opportunity for collaboration and knowledge to further expand TMC's global footprint and commitment to healthcare innovation.

Mitsui Fudosan Co., Ltd. announced that they will report Q3, 2025 results on Feb 07, 2025

Mitsui Fudosan Co., Ltd., H1 2025 Earnings Call, Nov 12, 2024

Mitsui Fudosan Co., Ltd., Q2 2025 Earnings Call, Nov 08, 2024

Mitsui Fudosan Co., Ltd. expected to report Q3 2025 results on February 6, 2025. This event was calculated by S&P Global (Created on November 8, 2024).

From October 1, 2024 to October 21, 2024, the company has repurchased 12,489,100 shares, representing 0.45% for ¥17,141.85 million. With this, the company has completed the repurchase of 29,532,900 shares, representing 1.05% for ¥39,999.91 million under the buyback announced on April 11, 2024.

The company closed its plan on October 21, 2024.

From July 1, 2024 to September 30, 2024, the company has repurchased 17,043,800 shares, representing 0.61% for ¥22,858.06 million. With this, the company has completed the repurchase of 17,043,800 shares, representing 0.61% for ¥22,858.06 million under the buyback announced on April 11, 2024.

Reiwa Travel, Inc. announced that it has received ¥4.8 billion in a round of funding co-led by returning investor SMBC-GB Growth No. 1 Fund, a fund co-managed by Global Brain Corporation, SMBC Venture Capital Co., Ltd., SMBC Venture Capital Management Co., Ltd., Sumitomo Mitsui Banking Corporation on September 9, 2024. The transaction included participation from new investors THE CREATIVE FUND No. 1, a fund managed by The Creative Fund, LLP., PKSHA Technology Inc., Fukoku CVC Fund, Resona Capital Investment Limited Partnership No. 8, a fund managed by Resona Capital Co., Ltd., Mitsui Fudosan Co., Ltd., X&KSK Fund, a fund managed by X&, returning investors ANRI No. 4 Fund, a fund managed by ANRI, JAFCO SV6 Series, a fund managed by JAFCO Group Co., Ltd., Chiba Dojo No. 3 Fund, a fund managed by Chiba Dojo Co., Ltd., Dawn Capital No.1 Investment Limited Partnership, a fund managed by Akatsuki Ventures, and others. The company has raised a total of ¥7 billion in funding till date.